PTCTHIGH SIGNALFINANCIAL10-K

PTCT's stockholders' equity improved substantially from deeply negative territory while the company added a new commercial product, Sephience, for PKU treatment.

The dramatic improvement in stockholders' equity from -$1.1B to -$205M suggests either a major capital raise, debt restructuring, or significant accounting adjustment that has meaningfully strengthened the balance sheet. The introduction of Sephience as a new commercial product represents portfolio expansion beyond their existing Translarna franchise, potentially diversifying revenue streams in the rare disease space.

Comparing 2026-02-19 vs 2025-02-27View on EDGAR →
FINANCIAL ANALYSIS

PTCT demonstrated strong growth with revenue expanding 36% to $265M while maintaining disciplined cost management through a 15% reduction in R&D expenses. The balance sheet transformation was striking, with total assets growing 70% to $2.9B and stockholders' equity improving substantially from deeply negative levels, though current liabilities also increased notably. The company maintained a solid cash position of nearly $1B, providing financial flexibility to support its expanding commercial operations and pipeline development.

FINANCIAL STATEMENT CHANGES
Stockholders Equity
Balance Sheet
+81.3%
-$1.1B→-$205.3M

Equity base grew 81.3% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Total Assets
Balance Sheet
+70%
$1.7B→$2.9B

Asset base grew 70% — expansion through organic growth, acquisitions, or capital deployment.

Current Liabilities
Balance Sheet
+66.7%
$581.0M→$968.4M

Current liabilities surged 66.7% — significant near-term obligations; verify ability to meet short-term debt.

Current Assets
Balance Sheet
+66.5%
$1.4B→$2.3B

Current assets grew 66.5% — improving short-term liquidity or inventory/receivables build.

Capital Expenditure
Cash Flow
+36.3%
$6.5M→$8.9M

Capital expenditure jumped 36.3% — major investment cycle underway; assess returns on deployment.

Revenue
P&L
+36.2%
$194.4M→$264.7M

Strong top-line growth of 36.2% — accelerating demand or successful expansion into new markets.

Cash & Equivalents
Balance Sheet
+26.3%
$779.7M→$984.6M

Cash grew 26.3% — improving liquidity position supports investment and shareholder returns.

SG&A Expense
P&L
+15.4%
$300.9M→$347.1M

SG&A increased modestly — likely reflects growth-related hiring or sales expansion investment.

R&D Expense
P&L
-14.8%
$534.5M→$455.2M

R&D spending cut 14.8% — could signal cost discipline or concerning reduction in innovation investment.

Total Liabilities
Balance Sheet
+10.7%
$2.8B→$3.1B

Liabilities increased 10.7% — monitor debt-to-equity ratio and interest coverage.

LANGUAGE CHANGES
NEW — 2026-02-19
PRIOR — 2025-02-27
ADDED
As of February 18, 2026, the registrant had 82,774,730 shares of Common Stock, $0.001 par value per share, outstanding.
Summary of Risk Factors We may be unable to continue to execute our commercial strategy for our products, fail to obtain renewal of, or satisfy the conditions of our marketing authorization for our products; Delays or failures in obtaining regulatory approval would materially impair our commercialization capabilities; We may be unable to continue to commercialize Translarna for nmDMD in the EEA if individual countries in the EU do not leverage Articles 117(3) and 5(1) of the EU Directive 2001/83 to allow continued commercial use of Translarna.
Business Overview We are a global biopharmaceutical company dedicated to the discovery, development and commercialization of clinically differentiated medicines for children and adults living with rare disorders.
We are advancing a robust and diversified pipeline of transformative medicines as part of our mission to provide access to best-in-class treatments for patients with unmet medical needs.
Our strategy is to leverage our scientific expertise and global commercial infrastructure to optimize value for our patients and other stakeholders.
+7 more — sign up free →
REMOVED
As of February 25, 2025, the registrant had 78,869,368 shares of Common Stock, $0.001 par value per share, outstanding.
Summary of Risk Factors We may be unable to continue to execute our commercial strategy for our products, fail to obtain renewal of, or satisfy the conditions of our marketing authorization for our products; Delays or failures in obtaining regulatory approval would materially impair our commercialization capabilities; We may be unable to continue to commercialize Translarna for nmDMD in the EEA if the EC adopts the negative opinion issued by the CHMP for the renewal of the existing conditional authorization for Translarna.
Business Overview We are a global biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders.
Our ability to innovate to identify new therapies and to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines.
Our mission is to provide access to best-in-class treatments for patients who have little to no treatment options.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →